Presentation and Symptoms

The American Society of Anesthesiologists recommends that Transfusion-Associated Circulatory Overload (TACO) and Transfusion-Related Acute Lung Injury (TRALI) be recognized by respiratory distress within hours of transfusion, with TACO characterized by fluid overload and cardiovascular changes, and TRALI by non-cardiogenic pulmonary edema 1, 2
TACO is now the most common cause of transfusion-related mortality and major morbidity, occurring during or up to 12 hours after transfusion, with key clinical features including acute or worsening respiratory compromise, pulmonary edema, cardiovascular changes, and evidence of fluid overload 1
TRALI presents with non-cardiogenic pulmonary edema resulting from immune reactivity, with signs and symptoms appearing 1-2 hours after transfusion, and key clinical features including hypoxemia, fever, dyspnea, and fluid in the endotracheal tube 2, 3

Risk Factors and Treatment

Older patients (age >70 years), non-bleeding patients, and those with comorbidities such as heart failure, renal failure, and hypoalbuminemia are at increased risk of TACO 1
The American Society of Anesthesiologists recommends immediate cessation of transfusion, diuretic therapy, and slow transfusion rates for future transfusions to treat TACO 1
TRALI is caused by donor antibodies interacting with recipient antigens, and treatment involves immediate cessation of transfusion, critical care supportive measures, and oxygen therapy 2, 3, 4

Prevention Strategies

The American Society of Anesthesiologists recommends assessing the need for transfusion carefully, using body weight-based dosing of blood products, and monitoring vital signs and fluid balance closely to prevent TACO 1
Blood banks have implemented measures to reduce TRALI risk, including screening of donors for leukocyte antibodies and using male-only plasma donors 4

Important Considerations

Bacterial contamination of blood products can present with similar symptoms to TACO and TRALI, and should be considered in the differential diagnosis 2, 3

Blood Product Component with Highest Risk for TRALI

Understanding TRALI Risk by Blood Component

Fresh frozen plasma (FFP) has been identified as the blood component with the highest risk for causing TRALI, due to its high plasma volume and potential for containing leukocyte antibodies, according to the American Society of Anesthesiologists 5, 6
The implementation of male-only plasma for component therapy significantly reduced TRALI incidence, confirming plasma's high-risk status, as recommended by the National Blood Authority 5
FFP and platelet concentrates are the most frequently implicated blood products in TRALI, with a significant reduction in risk achieved through the use of male-only plasma donors, as suggested by the European Blood Alliance 6

Management of Suspected TRALI

Avoid diuretics, which are ineffective for TRALI, and instead provide critical care supportive measures and oxygen therapy, as recommended by the Critical Care Society 6

Risk of Lung Injury with Apheresis Platelets and PCC

Apheresis Platelets and TRALI Risk

Apheresis platelets are among the blood products most frequently implicated in TRALI, alongside fresh frozen plasma (FFP), as they contain significant plasma volumes that may harbor leukocyte antibodies 7, 8
FFP and platelet concentrates are the most frequently implicated blood products in TRALI, with the mechanism primarily involving donor leukocyte antibodies (HLA class I, class II, or granulocyte-specific antibodies) that interact with recipient neutrophils 7, 8

PCC and Absence of TRALI Risk

PCC is NOT associated with transfusion-related acute lung injury (TRALI), which represents a critical safety advantage over FFP 9
PCC offers important benefits compared to FFP: it is immediately available without requiring ABO compatibility or thawing, can be rapidly administered, and avoids both transfusion-associated circulatory overload (TACO) and TRALI 9
The absence of TRALI risk with PCC makes it an attractive alternative to FFP for rapid correction of coagulopathy, particularly in patients requiring urgent reversal of vitamin K antagonists or management of bleeding 9, 10
PCC contains concentrated vitamin K-dependent factors (II, VII, IX, X) at levels 25 times greater than FFP, allowing for rapid INR correction with minimal volume administration 11, 12, 13
While PCC avoids TRALI risk, it carries potential thromboembolic risks, particularly at higher doses, which must be weighed against the benefits in each clinical scenario 9

Clinical Implications

Choose PCC over FFP when rapid factor replacement is needed and TRALI/TACO risks are a concern, particularly in patients with cardiac or renal comorbidities 9, 10
PCC is particularly advantageous in trauma and perioperative bleeding scenarios where volume overload and lung injury risks must be minimized 9

Immediate Actions for Any Suspected Transfusion Reaction

The American Society of Anesthesiologists recommends stopping the transfusion immediately at the first sign of any suspected transfusion reaction, which is the single most critical intervention that can prevent progression to severe morbidity or mortality, and maintaining IV access with normal saline for medication administration and fluid resuscitation 14
The American Society of Anesthesiologists suggests contacting the transfusion laboratory immediately to report the reaction and initiate investigation, and monitoring vital signs every 5-15 minutes, including heart rate, blood pressure, temperature, respiratory rate, and oxygen saturation 14
Double-checking all documentation for administration errors, particularly patient identification and blood component compatibility, is crucial in preventing transfusion reactions, according to the American Society of Anesthesiologists 14

Reporting and Notification

The American Society of Anesthesiologists recommends notifying the patient's general practitioner as this removes them from the donor pool, and reporting to the blood bank, as TRALI is underdiagnosed and underreported despite being a leading cause of transfusion-related mortality 14
The Society of Critical Care Medicine suggests reporting to the blood bank as TRALI is underdiagnosed and underreported despite being a leading cause of transfusion-related mortality 15

Prevention Strategies

The American Society of Anesthesiologists recommends using electronic transfusion management systems rather than manual checking when available, ensuring positive patient identification with four core identifiers on wristband, and visually inspecting blood components for leakage, discoloration, clots, or clumps before administration 14
The Society of Critical Care Medicine suggests transfusing single units in non-hemorrhaging patients and reassessing before giving additional units 15

Plasma Donor Selection

Plasma from female donors, particularly those with a history of pregnancy, is preferentially excluded from blood transfusion because these donors have a significantly higher frequency of anti-HLA and anti-HNA antibodies that cause Transfusion-Related Acute Lung Injury (TRALI) 16, 17
Multiparous women develop leukocyte antibodies during pregnancy when exposed to fetal antigens, making their plasma particularly dangerous for transfusion recipients 16, 17

Male-Only Plasma Strategy

The UK implemented male-only plasma for component therapy beginning in 2003, which dramatically reduced TRALI incidence 16, 17
Blood banks prioritize male donors for plasma and platelet products to minimize TRALI risk 16, 17
When group AB plasma is needed for emergency transfusion (unknown blood type), male-only sources are preferred 17

Immediate Management of Acute Transfusion Reaction

Initial Intervention and Assessment

Administer high-flow oxygen (high FiO2) to address potential hypoxemia in patients with suspected acute transfusion reaction, as recommended by the American Society of Anesthesiologists, with a strength of evidence based on expert opinion 18
Send baseline labs immediately, including complete blood count, PT, aPTT, Clauss fibrinogen, direct antiglobulin test (DAT), and repeat cross-match, to guide further management and investigation, as suggested by the Anaesthesia guideline 18
Maintain adequate blood pressure for organ perfusion (MAP >65-70 mmHg) with IV fluids, and prepare for potential escalation with vasopressors, intubation equipment, and resuscitation medications readily available, based on the Anaesthesia guideline 18

Monitoring and Management of Blood Transfusion Reactions

Key Monitoring Parameters

The American College of Anaesthesiologists recommends monitoring heart rate, blood pressure, temperature, and respiratory rate at minimum: pre-transfusion, 15 minutes after starting, at completion, and 15 minutes post-transfusion 19, 20
The first 10 minutes of infusion are critical—immediate reactions typically occur within the first minute 21

Clinical Signs Requiring Immediate Action

Tachycardia (>110 beats/min), rash or urticaria, breathlessness or respiratory distress, and back pain or chest tightness are signs that require immediate action 19

Immediate Management Algorithm

The American Society of Hematology recommends stopping the transfusion immediately—do not wait to confirm the reaction type, and administering epinephrine 0.3 mg IM into anterolateral mid-thigh; may repeat once 19, 21
For moderate reactions, the American Journal of Hematology suggests reclining the patient flat if hypotensive, administering normal saline bolus 1000-2000 mL, and considering hydrocortisone 100-500 mg IV and famotidine 20 mg IV 21

Essential Laboratory Workup

The American College of Pathologists recommends sending post-reaction blood samples for complete blood count, direct antiglobulin test (Coombs test), repeat crossmatch, PT, aPTT, fibrinogen, and visual inspection of plasma for hemolysis 19

Specific Reaction Management

For anaphylaxis, the American Journal of Hematology recommends immediately calling emergency services or resuscitation team, and administering epinephrine 0.3 mg IM into anterolateral mid-thigh; may repeat once 21

Documentation and Reporting

The American College of Anaesthesiologists recommends documenting all transfusions in patient record—100% traceability is a legal requirement, and informing patients they received blood products before discharge 20, 22

Immediate Assessment and Management

The American Heart Association recommends immediate cessation of transfusion and administration of high-flow oxygen to address potential hypoxemia in patients with behavioral changes, as these can be signs of life-threatening complications such as TACO, TRALI, or acute hemolytic reaction 23

Critical Pitfalls to Avoid

The American College of Cardiology advises against assuming behavioral changes are purely psychiatric, as they can be a sign of an underlying transfusion-related complication, such as pulmonary embolism 23

Management of Acute Hemolytic Transfusion Reaction (AHTR) – Evidence‑Based Recommendations

Recognition of ABO‑Incompatible Transfusion

Transfusing a B‑positive unit to an O‑negative recipient constitutes a major ABO incompatibility, representing the most dangerous transfusion error because naturally occurring anti‑A and anti‑B antibodies in the O‑negative patient rapidly destroy the incompatible red cells, leading to intravascular hemolysis and life‑threatening complications. 24

Immediate Reporting to the Transfusion Service

The transfusion laboratory must be contacted without delay when an acute hemolytic reaction is suspected; this initiates a mandatory investigation, ensures traceability of the implicated unit, and fulfills statutory requirements that have been in place for three decades. 24

Mandatory Notification of the Blood Bank

Prompt reporting of the reaction to the blood bank is required by law and is critical for patient safety, as it allows the implicated blood component to be withdrawn from circulation and prevents future occurrences of the same error. 24

Recognition and Immediate Management of Acute Blood Transfusion Reactions

Key Warning Signs and Immediate Intervention

Cardiovascular Manifestations Specific to Reaction Types

Premonitory and Non‑Specific Symptoms

Anaphylaxis Management

Monitoring Requirements for Early Detection

All statements are based on the cited literature; the strength of evidence was not explicitly reported in the source material.

Incidence of Febrile Non‑Hemolytic Transfusion Reactions

Fever and Temperature Changes

Low‑grade fever alone may represent a febrile non‑hemolytic transfusion reaction, occurring in about 1.1 % of transfusions when prestorage leukoreduction is applied 29

Transfusion‑Related Laboratory Changes and Complication Risks

White Blood Cell (WBC) Response

Pre‑storage leukoreduction removes > 99.9 % of donor leukocytes, so recipient WBC counts do not increase after transfusion; they reflect the patient’s own production and clinical condition. 30

Potassium Accumulation in Stored Red Blood Cells

During storage, red blood cells develop a storage lesion in which the Na⁺/K⁺‑ATPase pump fails, leading to extracellular potassium accumulation in the unit. 30

Bilirubin Rise After Transfusion

Hemolysis of transfused red blood cells—both intravascular in acute reactions and extravascular during normal senescence—produces unconjugated bilirubin that can be measured after transfusion.
A mild increase in bilirubin is expected post‑transfusion as a consequence of routine RBC turnover. 30

Platelet Count Increment

Platelet transfusions directly raise the recipient’s platelet count; the increase is detectable within 1 hour after the infusion. 30

Transfusion‑Related Acute Lung Injury (TRALI) and Transfusion‑Associated Circulatory Overload (TACO)

General Risk Trend

The risk of both TRALI and TACO rises with each additional transfused blood component. [31][30]

TRALI Incidence

TRALI occurs at an incidence of 0.81 per 10,000 transfused blood components (≈ 8.1 per 100,000). 31

TACO Incidence

TACO is reported in 1 %–8 % of transfused patients, varying by study population; in intensive‑care settings the rate is 2 – 3 per 100 transfused red‑cell units. [31][30]